Haralambos Gavras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Haralambos Gavras has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Irene Gavras
Hypertension and Atherosclerosis Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
15 shared publications Ekaterina Kintsurashvili
Hypertension and Atherosclerosis Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
5 shared publications- Roberto Jorge da Silva Franco
Universidade Estadual Paulista, Brazil
3 shared publications Anita L. DeStefano
Department of Neurology, Boston University School of Medicine , Boston , Massachusetts, USA 4 Department of Biostatistics, Boston University School of Public Health , Boston , Massachusetts, USA
2 shared publicationsAthanasios J. Manolis
The Hypertension Clinic, Tzanion Hospital, Piraeus, Greece
2 shared publicationsClinton T. Baldwin
Center for Human Genetics , Boston , Massachusetts, USA
2 shared publications
Latest Publications
- 1 January 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 210, 112948
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
- 1 January 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 210, 112948
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
- Open Access
- 1 May 2010
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 23 (5) , 562-568
Cardioprotective Effects of a Selective B2 Receptor Agonist of Bradykinin Post-Acute Myocardial Infarct
Background. The cardioprotective benefits of bradykinin are attributable to activation of its B2 receptor (B2R)–mediated actions and abolished by B2R a
- 1 May 2010
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 23 (5) , 562-568
Open AccessCardioprotective Effects of a Selective B2 Receptor Agonist of Bradykinin Post-Acute Myocardial Infarct
Background. The cardioprotective benefits of bradykinin are attributable to activation of its B2 receptor (B2R)–mediated actions and abolished by B2R a
- 10 February 2009
- Published by Hamdan Medical Journal in Journal of Medical Sciences
- Vol. 2 (1) , 25-28
Pathogenesis of Hypertension: A Review
Pathogenesis of Hypertension: A Review
- 10 February 2009
- Published by Hamdan Medical Journal in Journal of Medical Sciences
- Vol. 2 (1) , 25-28
Pathogenesis of Hypertension: A Review
Pathogenesis of Hypertension: A Review
- Open Access
- 1 January 2009
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 22 (1) , 41-45
Hypertension in Transgenic Mice With Brain-Selective Overexpression of the 2B-Adrenoceptor
Background. Previous studies have shown that the presynaptic α2B-adrenoceptor subtype in the central nervous system has a sympathoexcitatory function a
- 1 January 2009
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 22 (1) , 41-45
Open AccessHypertension in Transgenic Mice With Brain-Selective Overexpression of the 2B-Adrenoceptor
Background. Previous studies have shown that the presynaptic α2B-adrenoceptor subtype in the central nervous system has a sympathoexcitatory function a
- Open Access
- 1 October 2008
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 21 (10) , 1163-1168
Pleiotropic Effects of Statins May Improve Outcomes in Atherosclerotic Renovascular Disease
Background. Atherosclerotic renovascular disease (ARD) coexists with arterial obstructive disease in the coronary, cerebral, and peripheral arteries th
- 1 October 2008
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 21 (10) , 1163-1168
Open AccessPleiotropic Effects of Statins May Improve Outcomes in Atherosclerotic Renovascular Disease
Background. Atherosclerotic renovascular disease (ARD) coexists with arterial obstructive disease in the coronary, cerebral, and peripheral arteries th
- 1 May 2007
- Published by Elsevier in Vascular Pharmacology
- Vol. 46 (5) , 367-372
Inhibition of the α1D-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors
- 1 May 2007
- Published by Elsevier in Vascular Pharmacology
- Vol. 46 (5) , 367-372
Inhibition of the α1D-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors
- Open Access
- 1 November 2006
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 19 (11) , 1125-1128
Frequency of Coronary Artery Disease in Patients With Renal Artery Stenosis Without Clinical Manifestations of Coronary Insufficiency
Atherosclerotic renal artery stenosis (RAS) and coronary artery disease (CAD) arise from the same multiple risk factors. The purpose of this study was to assess the frequency of previously undiagnosed CAD in patients with angiographically confirmed RAS, by conducting coronary arteriography in the same setting. Of 57 consecutive patients referred for renal arteriography on clinical grounds during a 14-month period, 28 had no RAS and 6 had RAS, but previously documented CAD. Of the remainder 23 patients, 17 (74%; CI 56%–92%) had both RAS and CAD (7 single vessel, 4 two-vessel, and 7 multivessel disease). The clinical characteristics, such as age, blood pressure (BP) levels, signs of heart failure, were no different between those with and without CAD, although the 4 diabetic patients, the 4 patients with fundoscopic findings of grade III retinopathy, 11 of 14 with peripheral arterial disease, and 7 of 8 patients with prior stroke belonged in the CAD group. None developed complications as a result of the two consecutive procedures. The data suggest that in patients with RAS the frequency of silent CAD is high and cannot be predicted on clinical grounds alone, therefore coronary angiography should be routinely recommended in the same setting.
- 1 November 2006
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 19 (11) , 1125-1128
Open AccessFrequency of Coronary Artery Disease in Patients With Renal Artery Stenosis Without Clinical Manifestations of Coronary Insufficiency
Atherosclerotic renal artery stenosis (RAS) and coronary artery disease (CAD) arise from the same multiple risk factors. The purpose of this study was to assess the frequency of previously undiagnosed CAD in patients with angiographically confirmed RAS, by conducting coronary arteriography in the same setting. Of 57 consecutive patients referred for renal arteriography on clinical grounds during a 14-month period, 28 had no RAS and 6 had RAS, but previously documented CAD. Of the remainder 23 patients, 17 (74%; CI 56%–92%) had both RAS and CAD (7 single vessel, 4 two-vessel, and 7 multivessel disease). The clinical characteristics, such as age, blood pressure (BP) levels, signs of heart failure, were no different between those with and without CAD, although the 4 diabetic patients, the 4 patients with fundoscopic findings of grade III retinopathy, 11 of 14 with peripheral arterial disease, and 7 of 8 patients with prior stroke belonged in the CAD group. None developed complications as a result of the two consecutive procedures. The data suggest that in patients with RAS the frequency of silent CAD is high and cannot be predicted on clinical grounds alone, therefore coronary angiography should be routinely recommended in the same setting.
- Open Access
- 1 January 2005
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 18 (1) , 1-2
Report on the fifth annual Laragh conference: Interaction of the angiotensin converting enzyme (ACE) with the Renin-Angiotensin System, the Kinin System and Beyond
Since the year 2000, it has become an annual tradition for the American Society of Hypertension (ASH) to hold early in the year a research conference named in honor of its founder, Dr. John Laragh. This is an informal scientific forum, permitting exchange of the latest published and unpublished research data by a number of invited speakers who are considered to be experts in a particular field. The topic of interest is chosen every year by the president of the ASH, who is also responsible for setting the agenda and inviting the speakers.
- 1 January 2005
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 18 (1) , 1-2
Open AccessReport on the fifth annual Laragh conference: Interaction of the angiotensin converting enzyme (ACE) with the Renin-Angiotensin System, the Kinin System and Beyond
Since the year 2000, it has become an annual tradition for the American Society of Hypertension (ASH) to hold early in the year a research conference named in honor of its founder, Dr. John Laragh. This is an informal scientific forum, permitting exchange of the latest published and unpublished research data by a number of invited speakers who are considered to be experts in a particular field. The topic of interest is chosen every year by the president of the ASH, who is also responsible for setting the agenda and inviting the speakers.
- Open Access
- 1 January 2005
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 18 (1) , 18-22
Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy
Diabetes mellitus (DM) is known to cause increased arterial wall stiffness and increased cardiovascular risk, even in the absence of hypertension. This study was designed to investigate whether use of an angiotensin-converting enzyme (ACE) inhibitor may improve arterial stiffness in normotensive diabetics, using pulse wave velocity (PWV) as a surrogate marker. We studied 42 patients (26 with type 2 DM, aged 56.5 ± 9 years, 16 with type 1 DM, aged 41.5 ± 11 years) by measuring PWV at baseline (compared to 15 age- and gender-matched normal subjects) and after 6 months of treatment with perindopril (4 mg/d). At baseline, PWV was significantly higher in DM patients versus controls (13.09 ± 2.59 v 9.5 ± 1.6 m/sec, respectively, P < .001). After 6 months, PWV decreased significantly to 11.68 ± 3.08 m/sec (P < .003) for the whole DM group. However, the results were driven by the change in the younger type 1 DM (from 12.59 ± 1.59 to 10.35 ± 2.21 m/sec, P < .001), whereas in the type 2 DM it was insignificant (from 13.37 ± 3.0 to 12.42 ± 3.28 m/sec). Blood pressure and other hemodynamic and biochemical parameters remained unchanged. The results demonstrate that ACE inhibition can improve arterial elasticity and hence risk of cardiovascular complications even in normotensive diabetics. This short treatment was effective only in younger patients with type 1 diabetes, suggesting that early initiation of therapy before the onset of advanced structural alterations is likely to be more cardioprotective. Am J Hypertens 2005; 18:18–22 © 2005 American Journal of Hypertension, Ltd.
- 1 January 2005
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 18 (1) , 18-22
Open AccessArterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy
Diabetes mellitus (DM) is known to cause increased arterial wall stiffness and increased cardiovascular risk, even in the absence of hypertension. This study was designed to investigate whether use of an angiotensin-converting enzyme (ACE) inhibitor may improve arterial stiffness in normotensive diabetics, using pulse wave velocity (PWV) as a surrogate marker. We studied 42 patients (26 with type 2 DM, aged 56.5 ± 9 years, 16 with type 1 DM, aged 41.5 ± 11 years) by measuring PWV at baseline (compared to 15 age- and gender-matched normal subjects) and after 6 months of treatment with perindopril (4 mg/d). At baseline, PWV was significantly higher in DM patients versus controls (13.09 ± 2.59 v 9.5 ± 1.6 m/sec, respectively, P < .001). After 6 months, PWV decreased significantly to 11.68 ± 3.08 m/sec (P < .003) for the whole DM group. However, the results were driven by the change in the younger type 1 DM (from 12.59 ± 1.59 to 10.35 ± 2.21 m/sec, P < .001), whereas in the type 2 DM it was insignificant (from 13.37 ± 3.0 to 12.42 ± 3.28 m/sec). Blood pressure and other hemodynamic and biochemical parameters remained unchanged. The results demonstrate that ACE inhibition can improve arterial elasticity and hence risk of cardiovascular complications even in normotensive diabetics. This short treatment was effective only in younger patients with type 1 diabetes, suggesting that early initiation of therapy before the onset of advanced structural alterations is likely to be more cardioprotective. Am J Hypertens 2005; 18:18–22 © 2005 American Journal of Hypertension, Ltd.
- Open Access
- 1 January 2004
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 17 (1) , 98-99
Adrenergic receptors in hypertension and heart failure
The 4th Annual John H. Laragh Conference on Advances in Hypertension Research took place in the hotel Biltmore, in Coral Gables, Florida, on January 17 to 18, 2003. This is an annual event initiated in the year 2000 in honor of the founder of the American Society of Hypertension (ASH) and sponsored by the ASH. As in previous years, it was an informal scientific forum for which a central theme is chosen and a multidisciplinary group of experts in the field are invited to present their latest research data, exchange opinions, and debate controversial issues. This year’s theme was “Adrenergic Receptors in Hypertension and Heart Failure.” Unlike the renin–angiotensin system, whose contribution to hypertension and chronic heart failure (CHF) has been studied extensively and has resulted in salutary therapeutic advances, the role of the sympathetic nervous system (SNS) continues to be controversial. Recent research has generated new data on the regulation and function of various central or peripheral components of the SNS, as well as on the mechanisms of sympathetic excitation and inhibition. This conference represented a unique opportunity for an evaluation of this new knowledge and its potential therapeutic implications.
- 1 January 2004
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 17 (1) , 98-99
Open AccessAdrenergic receptors in hypertension and heart failure
The 4th Annual John H. Laragh Conference on Advances in Hypertension Research took place in the hotel Biltmore, in Coral Gables, Florida, on January 17 to 18, 2003. This is an annual event initiated in the year 2000 in honor of the founder of the American Society of Hypertension (ASH) and sponsored by the ASH. As in previous years, it was an informal scientific forum for which a central theme is chosen and a multidisciplinary group of experts in the field are invited to present their latest research data, exchange opinions, and debate controversial issues. This year’s theme was “Adrenergic Receptors in Hypertension and Heart Failure.” Unlike the renin–angiotensin system, whose contribution to hypertension and chronic heart failure (CHF) has been studied extensively and has resulted in salutary therapeutic advances, the role of the sympathetic nervous system (SNS) continues to be controversial. Recent research has generated new data on the regulation and function of various central or peripheral components of the SNS, as well as on the mechanisms of sympathetic excitation and inhibition. This conference represented a unique opportunity for an evaluation of this new knowledge and its potential therapeutic implications.